Does albumin-to-creatinine ratio tell me anything about hepatic fat on retatrutide?

Concretely: albumin-to-creatinine ratio · retatrutide.

I suspect the usual explanation for this is wrong, or at least incomplete.

I am aware this may have a boring answer. I would still like the boring answer stated clearly.

So what is the mechanism, and how well established is it?

Answer first: mild transaminase elevation is common in this population before any drug is involved, and the usual cause is hepatic steatosis rather than anything acute.

Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.

Gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.

The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.

New training, alcohol and over-the-counter products first. Then the interesting hypotheses.

The short version: enzymes in this class usually fall as weight falls, and a rise is a reason to look for a cause rather than to assume a drug effect.

Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.

Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.

Research-use material of unknown content is an unquantifiable variable in any such attribution.

Isolated mild elevation is common and usually improves with weight loss.

Start with the pattern. A hepatocellular pattern with alanine aminotransferase above aspartate aminotransferase points one way; a cholestatic pattern with alkaline phosphatase and gamma-glutamyl transferase points another.

Creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.

An isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.

Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.

Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.

Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.

edited 21 Jul 2024 by triple_agonist_q — added the placebo-arm figures

Reference intervals for alanine aminotransferase differ between laboratories and have been revised downward over time, so the same value can be normal on one report and elevated on another.

Very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.

Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.